Daily Dosing for Bedaquiline in Patients with Tuberculosis | Zendy

David H. Salinger | Zendy; Jerry Nedelman | Zendy; Carl M. Mendel | Zendy; Melvin Spigelman | Zendy; David Hermann | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Daily Dosing for Bedaquiline in Patients with Tuberculosis

Author(s) -

David H. Salinger,

Jerry Nedelman,

Carl M. Mendel,

Melvin Spigelman,

David Hermann

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00463-19

Subject(s) - bedaquiline , tuberculosis , dosing , regimen , medicine , antibiotics , surgery , mycobacterium tuberculosis , microbiology and biotechnology , pathology , biology

The bedaquiline regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB) in adults is a loading dose of 400 mg QD for 2 weeks followed by 200 mg thrice weekly (TIW) for 22 weeks. Most TB antibiotics administered with bedaquiline are given QD. Using pharmacokinetic simulations, we explored alternative QD bedaquiline regimens and determined that 200 mg QD for 8 weeks followed by 100 mg QD provides comparable exposures to the approved regimen. This simpler regimen is under clinical evaluation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research